Takeda Raises Guidance, Eyes Emerging Market Acquisition
Takeda sees an increase in core earnings offsetting the expected impact on its operating profit this fiscal year of the Ariad acquisition, and is eyeing another possible modest M&A deal in an undisclosed emerging market.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.